Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review.
Identifieur interne : 001590 ( Main/Exploration ); précédent : 001589; suivant : 001591Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review.
Auteurs : Pattarawadee Prayuenyong [Royaume-Uni, Thaïlande] ; Anand V. Kasbekar [Royaume-Uni] ; David M. Baguley [Royaume-Uni]Source :
- Frontiers in public health [ 2296-2565 ] ; 2020.
Descripteurs français
- KwdFr :
- MESH :
- administration et posologie : Antipaludiques, Antiviraux, Chloroquine, Hydroxychloroquine.
- étiologie : Acouphène, Perte d'audition.
- Humains, Santé publique, Urgences.
English descriptors
- KwdEn :
- Antimalarials (administration & dosage), Antiviral Agents (administration & dosage), COVID-19 (drug therapy), Chloroquine (administration & dosage), Emergencies (MeSH), Hearing Loss (etiology), Humans (MeSH), Hydroxychloroquine (administration & dosage), Ototoxicity (complications), Public Health (MeSH), SARS-CoV-2 (MeSH), Tinnitus (etiology).
- MESH :
- chemical , administration & dosage : Antimalarials, Antiviral Agents, Chloroquine, Hydroxychloroquine.
- complications : Ototoxicity.
- drug therapy : COVID-19.
- etiology : Hearing Loss, Tinnitus.
- Emergencies, Humans, Public Health, SARS-CoV-2.
Abstract
At this time of the COVID-19 pandemic, potentially effective treatments are currently under urgent investigation. Benefits of chloroquine and hydroxychloroquine for the treatment of COVID-19 infection have been proposed and clinical trials are underway. Chloroquine and hydroxychloroquine, typically used for the treatment of malaria and autoimmune diseases, have been considered for off-label use in several countries. In the literature, there are reports of ototoxic effects of the drugs causing damage to the inner ear structures, which then result in hearing loss, tinnitus, and/or imbalance. This mini-review represents a summary of the findings from a systematic search regarding ototoxicity of chloroquine and hydroxychloroquine in the published literature. The characteristics of sensorineural hearing loss and/or tinnitus after chloroquine or hydroxychloroquine treatment can be temporary but reports of persistent auditory and vestibular dysfunction exist. These are not frequent, but the impact can be substantial. Additionally, abnormal cochleovestibular development in the newborn was also reported after chloroquine treatment in pregnant women. The suggested dose of chloroquine for COVID-19 infection is considerably higher than the usual dosage for malaria treatment; therefore, it is plausible that the ototoxic effects will be greater. There are potential implications from this review for survivors of COVID-19 treated with chloroquine or hydroxychloroquine. Patient reports of hearing loss, tinnitus, or imbalance should be noted. Those with troublesome hearing loss, tinnitus and/or imbalance are encouraged to be referred for hearing evaluation and interventions once they are stable. Clinical trials of chloroquine or hydroxychloroquine should also consider including audiological monitoring in the protocol.
DOI: 10.3389/fpubh.2020.00252
PubMed: 32574312
PubMed Central: PMC7273970
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review.</title><author><name sortKey="Prayuenyong, Pattarawadee" sort="Prayuenyong, Pattarawadee" uniqKey="Prayuenyong P" first="Pattarawadee" last="Prayuenyong">Pattarawadee Prayuenyong</name><affiliation wicri:level="4"><nlm:affiliation>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham</wicri:regionArea><wicri:noRegion>Nottingham</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Prince of Songkla University, Songkhla</wicri:regionArea><wicri:noRegion>Songkhla</wicri:noRegion></affiliation></author><author><name sortKey="Kasbekar, Anand V" sort="Kasbekar, Anand V" uniqKey="Kasbekar A" first="Anand V" last="Kasbekar">Anand V. Kasbekar</name><affiliation wicri:level="4"><nlm:affiliation>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham</wicri:regionArea><wicri:noRegion>Nottingham</wicri:noRegion></affiliation></author><author><name sortKey="Baguley, David M" sort="Baguley, David M" uniqKey="Baguley D" first="David M" last="Baguley">David M. Baguley</name><affiliation wicri:level="4"><nlm:affiliation>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham</wicri:regionArea><wicri:noRegion>Nottingham</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32574312</idno><idno type="pmid">32574312</idno><idno type="doi">10.3389/fpubh.2020.00252</idno><idno type="pmc">PMC7273970</idno><idno type="wicri:Area/Main/Corpus">001322</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001322</idno><idno type="wicri:Area/Main/Curation">001322</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001322</idno><idno type="wicri:Area/Main/Exploration">001322</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review.</title><author><name sortKey="Prayuenyong, Pattarawadee" sort="Prayuenyong, Pattarawadee" uniqKey="Prayuenyong P" first="Pattarawadee" last="Prayuenyong">Pattarawadee Prayuenyong</name><affiliation wicri:level="4"><nlm:affiliation>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham</wicri:regionArea><wicri:noRegion>Nottingham</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Prince of Songkla University, Songkhla</wicri:regionArea><wicri:noRegion>Songkhla</wicri:noRegion></affiliation></author><author><name sortKey="Kasbekar, Anand V" sort="Kasbekar, Anand V" uniqKey="Kasbekar A" first="Anand V" last="Kasbekar">Anand V. Kasbekar</name><affiliation wicri:level="4"><nlm:affiliation>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham</wicri:regionArea><wicri:noRegion>Nottingham</wicri:noRegion></affiliation></author><author><name sortKey="Baguley, David M" sort="Baguley, David M" uniqKey="Baguley D" first="David M" last="Baguley">David M. Baguley</name><affiliation wicri:level="4"><nlm:affiliation>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham</wicri:regionArea><wicri:noRegion>Nottingham</wicri:noRegion></affiliation></author></analytic><series><title level="j">Frontiers in public health</title><idno type="ISSN">2296-2565</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antimalarials (administration & dosage)</term><term>Antiviral Agents (administration & dosage)</term><term>COVID-19 (drug therapy)</term><term>Chloroquine (administration & dosage)</term><term>Emergencies (MeSH)</term><term>Hearing Loss (etiology)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Ototoxicity (complications)</term><term>Public Health (MeSH)</term><term>SARS-CoV-2 (MeSH)</term><term>Tinnitus (etiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acouphène (étiologie)</term><term>Antipaludiques (administration et posologie)</term><term>Antiviraux (administration et posologie)</term><term>Chloroquine (administration et posologie)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (administration et posologie)</term><term>Perte d'audition (étiologie)</term><term>Santé publique (MeSH)</term><term>Urgences (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antimalarials</term><term>Antiviral Agents</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antipaludiques</term><term>Antiviraux</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Ototoxicity</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hearing Loss</term><term>Tinnitus</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Acouphène</term><term>Perte d'audition</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Emergencies</term><term>Humans</term><term>Public Health</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Santé publique</term><term>Urgences</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">At this time of the COVID-19 pandemic, potentially effective treatments are currently under urgent investigation. Benefits of chloroquine and hydroxychloroquine for the treatment of COVID-19 infection have been proposed and clinical trials are underway. Chloroquine and hydroxychloroquine, typically used for the treatment of malaria and autoimmune diseases, have been considered for off-label use in several countries. In the literature, there are reports of ototoxic effects of the drugs causing damage to the inner ear structures, which then result in hearing loss, tinnitus, and/or imbalance. This mini-review represents a summary of the findings from a systematic search regarding ototoxicity of chloroquine and hydroxychloroquine in the published literature. The characteristics of sensorineural hearing loss and/or tinnitus after chloroquine or hydroxychloroquine treatment can be temporary but reports of persistent auditory and vestibular dysfunction exist. These are not frequent, but the impact can be substantial. Additionally, abnormal cochleovestibular development in the newborn was also reported after chloroquine treatment in pregnant women. The suggested dose of chloroquine for COVID-19 infection is considerably higher than the usual dosage for malaria treatment; therefore, it is plausible that the ototoxic effects will be greater. There are potential implications from this review for survivors of COVID-19 treated with chloroquine or hydroxychloroquine. Patient reports of hearing loss, tinnitus, or imbalance should be noted. Those with troublesome hearing loss, tinnitus and/or imbalance are encouraged to be referred for hearing evaluation and interventions once they are stable. Clinical trials of chloroquine or hydroxychloroquine should also consider including audiological monitoring in the protocol.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32574312</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-2565</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review.</ArticleTitle><Pagination><MedlinePgn>252</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2020.00252</ELocationID><Abstract><AbstractText>At this time of the COVID-19 pandemic, potentially effective treatments are currently under urgent investigation. Benefits of chloroquine and hydroxychloroquine for the treatment of COVID-19 infection have been proposed and clinical trials are underway. Chloroquine and hydroxychloroquine, typically used for the treatment of malaria and autoimmune diseases, have been considered for off-label use in several countries. In the literature, there are reports of ototoxic effects of the drugs causing damage to the inner ear structures, which then result in hearing loss, tinnitus, and/or imbalance. This mini-review represents a summary of the findings from a systematic search regarding ototoxicity of chloroquine and hydroxychloroquine in the published literature. The characteristics of sensorineural hearing loss and/or tinnitus after chloroquine or hydroxychloroquine treatment can be temporary but reports of persistent auditory and vestibular dysfunction exist. These are not frequent, but the impact can be substantial. Additionally, abnormal cochleovestibular development in the newborn was also reported after chloroquine treatment in pregnant women. The suggested dose of chloroquine for COVID-19 infection is considerably higher than the usual dosage for malaria treatment; therefore, it is plausible that the ototoxic effects will be greater. There are potential implications from this review for survivors of COVID-19 treated with chloroquine or hydroxychloroquine. Patient reports of hearing loss, tinnitus, or imbalance should be noted. Those with troublesome hearing loss, tinnitus and/or imbalance are encouraged to be referred for hearing evaluation and interventions once they are stable. Clinical trials of chloroquine or hydroxychloroquine should also consider including audiological monitoring in the protocol.</AbstractText><CopyrightInformation>Copyright © 2020 Prayuenyong, Kasbekar and Baguley.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prayuenyong</LastName><ForeName>Pattarawadee</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasbekar</LastName><ForeName>Anand V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baguley</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Hearing Sciences, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004630" MajorTopicYN="N">Emergencies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034381" MajorTopicYN="N">Hearing Loss</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081015" MajorTopicYN="N">Ototoxicity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014012" MajorTopicYN="N">Tinnitus</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">chloroquine</Keyword><Keyword MajorTopicYN="Y">hearing loss</Keyword><Keyword MajorTopicYN="Y">hydroxychloroquine</Keyword><Keyword MajorTopicYN="Y">ototoxicity</Keyword><Keyword MajorTopicYN="Y">tinnitus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32574312</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2020.00252</ArticleId><ArticleId IdType="pmc">PMC7273970</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clin Rheumatol. 2007 Nov;26(11):1809-10</Citation><ArticleIdList><ArticleId IdType="pubmed">17594118</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation><ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId></ArticleIdList></Reference><Reference><Citation>Laryngoscope Investig Otolaryngol. 2017 Mar 16;2(2):69-79</Citation><ArticleIdList><ArticleId IdType="pubmed">28894825</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Otolaryngol. 1968 Oct;88(4):370-2</Citation><ArticleIdList><ArticleId IdType="pubmed">5302911</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatol Int. 2000;19(5):203-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10984140</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Otolaryngol. 1985 Mar-Apr;99(3-4):387-92</Citation><ArticleIdList><ArticleId IdType="pubmed">4013729</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Otolaryngol. 1964 Oct;80:407-12</Citation><ArticleIdList><ArticleId IdType="pubmed">14198705</ArticleId></ArticleIdList></Reference><Reference><Citation>J Laryngol Otol. 1979 Aug;93(8):809-15</Citation><ArticleIdList><ArticleId IdType="pubmed">490032</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Rheumatol. 1998 Jul-Aug;16(4):472-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9706431</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologist. 2020 Apr 2;60(3):e137-e154</Citation><ArticleIdList><ArticleId IdType="pubmed">30835787</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Audiol. 2018 Nov/Dec;29(10):936-947</Citation><ArticleIdList><ArticleId IdType="pubmed">30479266</ArticleId></ArticleIdList></Reference><Reference><Citation>Otolaryngol Head Neck Surg. 1996 Mar;114(3):491-3</Citation><ArticleIdList><ArticleId IdType="pubmed">8649890</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188</Citation><ArticleIdList><ArticleId IdType="pubmed">32164085</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 24;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32208486</ArticleId></ArticleIdList></Reference><Reference><Citation>J Laryngol Otol. 1978 Aug;92(8):701-3</Citation><ArticleIdList><ArticleId IdType="pubmed">681846</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670</Citation><ArticleIdList><ArticleId IdType="pubmed">32196083</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Opt. 2012 Oct;17(10):106003</Citation><ArticleIdList><ArticleId IdType="pubmed">23224002</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pediatr Otorhinolaryngol. 2002 Jan 11;62(1):53-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11738695</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Daru. 2014 Jan 22;22(1):20</Citation><ArticleIdList><ArticleId IdType="pubmed">24450358</ArticleId></ArticleIdList></Reference><Reference><Citation>An Bras Dermatol. 2018 Jun;93(3):469-470</Citation><ArticleIdList><ArticleId IdType="pubmed">29924251</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 2004;13(4):223-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15176656</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation><ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Rheum Dis. 2011 Feb;14(1):e1-2</Citation><ArticleIdList><ArticleId IdType="pubmed">21303469</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Mar 20;:105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Glob J Health Sci. 2013 Jun 15;5(5):102-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23985111</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Mar 09;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Res Pract. 2020 Apr 9;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32363221</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Rev Med Pharmacol Sci. 2011 Jun;15(6):601-36</Citation><ArticleIdList><ArticleId IdType="pubmed">21796866</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 Apr 8;369:m1432</Citation><ArticleIdList><ArticleId IdType="pubmed">32269046</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li><li>Thaïlande</li></country><region><li>Angleterre</li><li>Nottinghamshire</li></region><settlement><li>Nottingham</li></settlement><orgName><li>Université de Nottingham</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Prayuenyong, Pattarawadee" sort="Prayuenyong, Pattarawadee" uniqKey="Prayuenyong P" first="Pattarawadee" last="Prayuenyong">Pattarawadee Prayuenyong</name></region><name sortKey="Baguley, David M" sort="Baguley, David M" uniqKey="Baguley D" first="David M" last="Baguley">David M. Baguley</name><name sortKey="Baguley, David M" sort="Baguley, David M" uniqKey="Baguley D" first="David M" last="Baguley">David M. Baguley</name><name sortKey="Baguley, David M" sort="Baguley, David M" uniqKey="Baguley D" first="David M" last="Baguley">David M. Baguley</name><name sortKey="Kasbekar, Anand V" sort="Kasbekar, Anand V" uniqKey="Kasbekar A" first="Anand V" last="Kasbekar">Anand V. Kasbekar</name><name sortKey="Kasbekar, Anand V" sort="Kasbekar, Anand V" uniqKey="Kasbekar A" first="Anand V" last="Kasbekar">Anand V. Kasbekar</name><name sortKey="Kasbekar, Anand V" sort="Kasbekar, Anand V" uniqKey="Kasbekar A" first="Anand V" last="Kasbekar">Anand V. Kasbekar</name><name sortKey="Prayuenyong, Pattarawadee" sort="Prayuenyong, Pattarawadee" uniqKey="Prayuenyong P" first="Pattarawadee" last="Prayuenyong">Pattarawadee Prayuenyong</name><name sortKey="Prayuenyong, Pattarawadee" sort="Prayuenyong, Pattarawadee" uniqKey="Prayuenyong P" first="Pattarawadee" last="Prayuenyong">Pattarawadee Prayuenyong</name></country><country name="Thaïlande"><noRegion><name sortKey="Prayuenyong, Pattarawadee" sort="Prayuenyong, Pattarawadee" uniqKey="Prayuenyong P" first="Pattarawadee" last="Prayuenyong">Pattarawadee Prayuenyong</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001590 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001590 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32574312
|texte= Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32574312" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |